Efficacy and safety of edaravone dexborneol in acute ischemic stroke: systematic review and meta-analysis of randomized controlled trials
- 6 March 2025
- journal article
- review article
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 398 (8) , 9569-9582
Abstract
Introduction Stroke is a leading cause of global morbidity and mortality, with acute ischemic stroke (AIS) accounting for most cases. Despite advancements in reperfusion therapies, many patients do not achieve sufficient reperfusion, necessitating effective neuroprotective interventions. This meta-analysis evaluates the efficacy and safety of Edaravone Dexborneol (ED) compared to standard therapies in AIS treatment. Methods A systematic review and meta-analysis were conducted according to PRISMA guidelines, including randomized controlled trials (RCTs) investigating ED in AIS. Primary outcomes included Modified Rankin Scale (mRS ≤ 1) at 90 days and changes in National Institutes of Health Stroke Scale (NIHSS) scores. Pooled effect sizes were calculated using random-effects models. Results Five RCTs with 2,535 patients (1,263 ED, 1,272 control) were included. ED significantly improved the odds of achieving mRS ≤ 1 at 90 days (OR = 1.47, 95% CI [1.25–1.74], p < 0.00001). While NIHSS score changes at 14 days were not significant (p = 0.35), ED showed significant improvement at 30 days (MD = -1.77, 95% CI [-2.82 to -0.72], p = 0.0009). ED also significantly reduced the risk of hemorrhagic transformation (OR = 0.47, 95% CI [0.24–0.92], p = 0.03) and mortality rates were lower in the ED group but not statistically significant (OR = 0.66, 95% CI [0.41–1.06], p = 0.08, I2 = 1%). Conclusion ED demonstrates significant neuroprotective benefits in AIS by improving functional outcomes and reducing the risk of hemorrhagic transformation. However, further studies with larger sample sizes must confirm these findings and optimize treatment protocols.Keywords
This publication has 22 references indexed in Scilit:
- Progress in Borneol Intervention for Ischemic Stroke: A Systematic ReviewFrontiers in Pharmacology, 2021
- Edaravone Dexborneol Versus Edaravone Alone for the Treatment of Acute Ischemic StrokeStroke, 2021
- Clinical effects and safety of edaravone in treatment of acute ischaemic stroke: A meta‐analysis of randomized controlled trialsJournal of Clinical Pharmacy and Therapeutics, 2021
- Safety and efficacy of Edaravone Dexborneol versus edaravone for patients with acute ischaemic stroke: a phase II, multicentre, randomised, double-blind, multiple-dose, active-controlled clinical trialStroke and Vascular Neurology, 2019
- 2014 Chinese guidelines for secondary prevention of ischemic stroke and transient ischemic attackInternational Journal of Stroke, 2017
- Rayyan—a web and mobile app for systematic reviewsSystematic Reviews, 2016
- Neuroprotection in acute stroke: targeting excitotoxicity, oxidative and nitrosative stress, and inflammationThe Lancet Neurology, 2016
- A critical assessment of edaravone acute ischemic stroke efficacy trials: is edaravone an effective neuroprotective therapy?Expert Opinion on Pharmacotherapy, 2010
- A new formulation for orally disintegrating tablets using a suspension spray-coating methodInternational Journal of Pharmaceutics, 2009
- Outline of the Japanese Guidelines for the Management of Stroke 2004 and Subsequent RevisionInternational Journal of Stroke, 2008